Tina Nova

Tina Nova

Président chez EXAGEN INC.

Fortune : 550 285 $ au 30/09/2026

73 ans
Health Technology
Commercial Services
Health Services

Profil

Dr. Tina S.
Nova is an Independent Director at Tang Capital Acquisition Corp., an Independent Director at Azenta, Inc., an Executive Chairman at Exagen, Inc., a Chief Executive Officer & Director at GenomeDx, Inc. (California) and a Venture Partner at Tullis Health Investors, Inc. She is on the Board of Directors at Tang Capital Acquisition Corp., Aurinia Pharmaceuticals, Inc., Azenta, Inc., GenomeDx, Inc. (California), Viridos, Inc., Xequel Bio, Inc., UC San Diego Foundation, University of San Diego and Rady Pediatric Genomics & Systems Medicine Institute.
Dr. Nova was previously employed as a General Manager-Decipher Urologic Cancers by Veracyte, Inc., an Independent Non-Executive Director by Olink Holding AB, a President, Chief Executive Officer & Director by Decipher Biosciences, Inc., an Independent Director by OpGen, Inc., an Independent Director by Veracyte, Inc., a President & Chief Executive Officer by Molecular Stethoscope, Inc., an Executive Vice President & General Manager by Illumina, Inc., an Independent Director by NS Wind Down Co., Inc., an Independent Director by Adamis Pharmaceuticals Corp., an Independent Director by Arena Pharmaceuticals, Inc., a Chairman by Biocom, Inc., a President, Chief Executive Officer & Director by Genoptix, Inc., a President & Chief Operating Officer by Nanogen, a President & Chief Executive Officer by Nanogen, Inc., a Chief Operating Officer by Selective Genetics, Inc., and an Executive Director-New Leads Discovery by Ligand Pharmaceuticals, Inc. She also served on the board at Cypress Bioscience, Inc., Heska Corp.
and CONNECT.
She received her undergraduate degree from the University of California, Irvine and a doctorate degree from the University of California, Riverside.

Détentions connues dans des sociétés publiques

SociétéDateNombre d'actionsValorisationDate de valorisation
06/02/2026 15 772 ( 0,04 % ) 550 285 $ 30/09/2026
04/06/2026 0 ( -.--% ) - $ 30/09/2026
15/04/2026 0 ( -.--% ) - $ 30/09/2026

Postes actifs de Tina Nova

SociétésPosteDébut
EXAGEN INC. Président 19/01/2023
AZENTA, INC. Directeur/Membre du Conseil 31/01/2023
AURINIA PHARMACEUTICALS INC. Directeur/Membre du Conseil 15/05/2025
Directeur/Membre du Conseil -
Directeur/Membre du Conseil -
Private Equity Investor -
Directeur Général 01/08/2018
Directeur/Membre du Conseil 09/11/2016
Rady Pediatric Genomics & Systems Medicine Institute
Directeur/Membre du Conseil -
░░░░░░░░░░ ░░ ░░░ ░░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ -

Anciens postes connus de Tina Nova

SociétésPosteFin
░░░░░░░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░░░░ -
░░░░░░░░ ░░░ ░░░░ ░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░░ ░░░░ ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░░░░
Voir l'expérience en détail de Tina Nova

Formation de Tina Nova

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Relations

71

Relations au 1er degré

30

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Sociétés liées

Entreprise privées30

Health Technology

Health Services

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Commercial Services

Health Services

Commercial Services

Health Technology

Health Technology

Finance

Consumer Services

Consumer Services

Consumer Services

Health Technology

Commercial Services

Health Services

Health Technology

Commercial Services

Health Technology

Commercial Services

Health Technology

Health Services

Rady Pediatric Genomics & Systems Medicine Institute

Commercial Services

Miscellaneous

Health Technology

Health Technology

🔇